Barcelona 2022

---

PG1 Part I: Cardiovascular and neurological consequences of obstructive sleep apnoea: An update

Postgraduate Course
Chairs: M. Bonsignore (Palermo, Italy), M. Bradicich (Zollikerberg, Switzerland)
Aims: to summarise the current knowledge of the many clinical faces of obstructive sleep apnoea (OSA) characterised by a variable degree of daytime sleepiness, gender differences of OSA symptoms and differences in the presence of comorbid insomnia, resulting in various comorbidities. It will cover the heterogeneity of OSA and its cognitive outcomes, especially in terms of attention and executive functions, and the potential bidirectional relationship with dementia, focusing on early identification, prevention and treatment strategies. The physiological and biochemical mechanisms connecting OSA with metabolic syndrome and diabetes, clinically meaningful phenotyping, improved prognosis and personalised treatment will be covered. The impact of the severity of OSA on the risk and outcomes of cardiovascular diseases and evidence of the impact of OSA treated with or without continuous positive airway pressure (CPAP) on morbidity and mortality outcomes will be discussed. The challenges facing sleep medicine regarding the important effect of CPAP on patient outcomes and the role of compliance will be highlighted.

Clinical OSA phenotypes from sleepiness to mild and asymptomatic OSA and their relevance S. Schiza (Heraklion, Greece)
Stroke, cognitive impairment and OSA: a bidirectional relationship? P. Jennum (Glostrup, Denmark)
Various pathophysiological mechanisms leading to cardiovascular sequalae of OSA and their relevance C. Lombardi (Milano (MI), Italy)
What is the impact of OSA treated with or without CPAP on cardiovascular morbidity and mortality outcomes? D. Testelmans (Leuven, Belgium)
Interactive cases S. Schiza (Heraklion, Greece), C. Lombardi (Milano (MI), Italy), D. Testelmans (Leuven, Belgium), P. Jennum (Glostrup, Denmark)